CAFs-derived PDGF-BB activates the glycogen synthase kinase 3β (GSK3β)/P65 pathway to promote trans-endothelial migration of tumor cells, and stimulates downstream c-Jun N-terminal kinase (JNK) and ERK1/2 pathways to induce intratumoral lymphangiogenesis [107], which suggests that targeting PDGF-BB/PDGF receptor β can inhibit tumor growth and lymphatic metastasis in CCA. Here, GSK3B is linked to neoplasm.